

## Global Biosimilars Market – Products, Applications and Regulations

“The report reviews, analyzes and projects the global market for Biosimilars for the period 2017-2026. The market for Biosimilar product types analyzed in this study comprises Monoclonal Antibodies, Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Insulin and Other product types (including Interferons, Follitropins, and Recombinant Proteins etc.). The report also encompasses the market analysis for Therapeutic Areas consisting Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other therapeutic areas (including Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.).”

Published: January 2021

Report Code: BT010

Pages: 356

Charts: 223


Price: \$4050 Single User License, \$6750 Enterprise License

### Report Synopsis

Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies’ commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to ‘build versus buy’ is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L’s. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.

Global market for Biosimilars is dominated by Oncology, estimated at US\$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US\$24.8 billion by 2026.

Global Biosimilars Market (2020 & 2026) by Product Type



Source: Industry Experts, Inc. <https://industry-experts.com>

### Research Findings & Coverage

- Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
- The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
- mAbs - All the Rage in Biosimilars’ New Wave
- Patent Expirations of Major Biologics Leads Way for Biosimilars
- Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
- Availability of Biosimilar May Affect Biologic Drug Pricing
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled – 36
- The industry guide includes the contact details for 155 companies

### Product Outline

The report analyzes the market for the following key product types of Biosimilars:

- Monoclonal Antibodies (mAB)
- Erythropoietin (EPO)
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Insulin
- Others (includes Interferons, Follitropins, Recombinant Proteins etc.)

Therapeutic areas of Biosimilars analyzed in this study comprise the following:

- Oncology
- Autoimmune Disorders
- Blood Disorders
- Growth Hormone Deficiency
- Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

### Analysis Period, Units and Growth Rates

- The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US\$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026

### Geographic Coverage

- **North America** (The United States, Canada and Mexico)
- **Europe** (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
- **Asia-Pacific** (China, India, Japan, South Korea and Rest of Asia-Pacific)
- **Rest of World** (Brazil, Israel and Other Rest of World)

## SAMPLE COMPANY PROFILE

### ELI LILLY AND COMPANY (THE UNITED STATES)

Lilly Corporate Center, Indianapolis, In 46285, United States  
Phone: 317.276.2000  
Website: www.lilly.com

#### Business Overview

Established in 1876, Eli Lilly and Company (Eli) is engaged in providing high quality therapeutic compounds to the patients worldwide. The company’s products are used to diseases such as Diabetes, Cancer, Cardiovascular, Neuroscience, Critical Care Musculoskeletal and Men’s Health. Eli provides Basaglar, which is a biosimilar insulin glargine injection available in 100 units /mL concentration. The product is long acting insulin compiled with a support design to make it a user friendly to the beginners. It is employed to manage the high blood sugar levels in adults and children suffering with type 1 diabetes and adults with type 2 diabetes. The company is engaged in the discovery, development, manufacture and marketing of human pharmaceutical products. The products of the company are distributed through facilities in the United States (U.S.), Puerto Rico, and 8 other countries. The internal pharmaceutical research unit of the company focuses primarily on the areas of oncology, diabetes, neurodegeneration, immunology, and pain.

#### Product Analysis

Product	Description
Baqsimi®	Baqsimi® (glucagon), a nasal powder formulation for the treatment of severe hypoglycemia in patients with diabetes (approved in the U.S. and Europe in 2019)
Basaglar®	Basaglar® (insulin glargine injection), a long-acting human insulin analog for the treatment of diabetes (launched in Japan and Europe under the trade name Abasaglar™)
Forteo®	Forteo®, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women
Humalog®	Humalog®, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, and insulin lispro, insulin analogs for the treatment of diabetes
Humatrope®	Humatrope®, for the treatment of human growth hormone deficiency and certain pediatric growth conditions • Humulin®, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500, human insulins of recombinant DNA origin for the treatment of diabetes
Jardiance®	Jardiance®, for the treatment of type 2 diabetes and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease • Trajenta®, for the treatment of type 2 diabetes


.....more

## SAMPLE TABLE/CHART

Glance at 2020 Global Biosimilars Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World



European Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million



## KEY PLAYERS PROFILED

- Amgen Inc.
- AXZO GmbH
- BIOCAD
- Biogen, Inc.
- Bioton S.A.
- C.H. Boehringer Sohn AG & Co., KG.
- Coherus Biosciences
- Creative BioMart
- Dong-A Socio Group
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- Genor Biopharma Co., Ltd.
- Hetero Drugs Limited
- Insud Pharma SL
- Intas Pharmaceuticals Ltd.
- Kashiv Biosciences LLC
- LG Chem
- Lupin Limited
- Mylan, Inc
- Pfizer, Inc.
- Reliance Life Sciences Pvt. Ltd.
- Sandoz International GmbH
- Shanghai Henlius Biotech, Inc.
- STADA Arzneimittel AG
- Teva Pharmaceutical Industries Limited
- Wockhardt Limited

.....more

## TABLE OF CONTENTS

### PART A: GLOBAL MARKET PERSPECTIVE ..... 1

#### 1. INTRODUCTION .....1

##### 1.1 Product Outline..... 4

##### 1.1.1 Biosimilars Defined ..... 4

##### 1.1.2 Backdrop ..... 5

##### 1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act)..... 6

##### 1.1.3.1 Data Exclusivity ..... 6

##### 1.1.4 Steps Involved in Biosimilar Synthesis ..... 7

##### 1.1.5 Key Regulatory Authorization Pathway – Synopsis .7

##### 1.1.6 Biosimilars Types ..... 8

##### 1.1.6.1 Monoclonal Antibodies (mAb or moAB) ..... 8

##### 1.1.6.1.1 Production Process ..... 8

##### 1.1.6.1.1.1 Hybridoma Cell Production ..... 8

##### 1.1.6.1.2 Therapeutic Applications ..... 9

##### 1.1.6.2 Erythropoietin (EPO) ..... 9

##### 1.1.6.2.1 Functions of EPO ..... 10

##### 1.1.6.2.2 Mechanism of Action ..... 10

##### 1.1.6.2.3 Synthesis and Regulation ..... 11

##### 1.1.6.2.4 Uses in Medicine ..... 11

##### 1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF) ... 11

##### 1.1.6.3.1 Biological Function ..... 11

##### 1.1.6.3.2 Genetics ..... 12

##### 1.1.6.3.3 Use in Therapeutics ..... 12

##### 1.1.6.4 Insulin ..... 13

##### 1.1.6.4.1 Biosimilar Insulin ..... 14

##### 1.1.6.4.2 The Complexity in Producing Biosimilar Insulin ..... 15

##### 1.1.6.4.3 Biosimilar Insulins and the Regulatory Environment Surrounding Them ..... 15

##### 1.1.6.4.4 The Market for Biosimilar Insulins ..... 16

##### 1.1.6.5 Interferons ..... 17

##### 1.1.6.5.1 Interferon Categorization ..... 17

##### 1.1.6.5.2 Functions of Interferons ..... 17

##### 1.1.6.5.3 Interferon Alfa ..... 18

##### 1.1.6.5.4 Interferon Beta-1a ..... 18

##### 1.1.6.5.5 Interferon Gamma ..... 19

##### 1.1.6.6 Human Growth Hormone ..... 20

##### 1.1.6.6.1 Recombinant Human Growth Hormone ... 20

##### 1.1.6.6.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars 21

##### 1.1.6.7 Other Biosimilars ..... 21

##### 1.1.7 Biosimilars Therapeutic Areas..... 22

##### 1.1.7.1 Oncology ..... 22

##### 1.1.7.1.1 Biosimilar G-CSF ..... 24

##### 1.1.7.2 Autoimmune Diseases ..... 25

##### 1.1.7.3 Blood Disorders..... 27

##### 1.1.7.4 Growth Hormone Deficiency (GHD) ..... 28

##### 1.1.7.4.1 Growth Hormone Deficiency in Children .. 29

##### 1.1.7.5 Infectious Diseases ..... 29

##### 1.1.7.5.1 Treatment of Infectious Diseases..... 30

#### 2. REGULATORY LANDSCAPE.....31

##### 2.1 The United States ..... 31

##### 2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product ..... 31

##### 2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product..... 32

##### 2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 ..... 32

##### 2.1.4 FDA Issues New Regulatory Updates in 2020.. 32

##### 2.2 European ..... 33

##### 2.3 The World Health Organization (WHO)..... 34

##### 2.4 Canada ..... 35

##### 2.5 South Korea ..... 36

##### 2.6 China ..... 36

##### 2.7 India ..... 37

##### 2.8 Japan ..... 39

##### 2.9 Mexico ..... 40

##### 2.10 Brazil ..... 40

##### 2.11 Argentina ..... 40

#### 3. KEY MARKET TRENDS.....41

##### 3.1 mAbs - All The Rage In Biosimilars' New Wave .. 41

##### 3.1.1 The Buildup to the Biosimilar Industry..... 41

##### 3.1.2 Biosimilars of mAbs Approved: A Sneak Preview . 43

##### 3.2 Patent Expirations of Major Biologics Leads Way for Biosimilars..... 44

##### 3.3 Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation ..... 45

##### 3.4 Availability of Biosimilar May Affect Biologic Drug Pricing ..... 46

##### 3.5 Asia-Pacific Witnessing a Boom of Biosimilars ... 47

#### 4. RECENT BIOSIMILARS APPROVALS .....50

#### 5. KEY GLOBAL PLAYERS.....55

##### Amgen Inc. (The United States)..... 55

##### AXXO GmbH (Germany) ..... 56

##### BIOCAD (Russia) ..... 57

##### Biogen, Inc. (The United States)..... 58

##### Bioton S.A. (Poland) ..... 58

##### C.H. Boehringer Sohn Ag & Co., Kg. (Germany)..... 59

##### Coherus Biosciences (The United States) ..... 59

##### Creative BioMart (The United States) ..... 60

##### Dong-A Socio Group (South Korea) ..... 61

##### Dr. Reddy's Laboratories Ltd. (India) ..... 62

##### Eli Lilly and Company (The United States) ..... 63

##### Genor Biopharma Co., Ltd. (China)..... 64

##### Hetero Drugs Limited (India) ..... 65

##### Insud Pharma SL (Spain) ..... 66

##### mAbxience SA (Spain) ..... 66

##### Intas Pharmaceuticals Ltd. (India)..... 67

##### Kashiv Biosciences Llc (The United States) ..... 68

##### LG Chem (South Korea) ..... 69

##### Lupin Limited (India) ..... 70

##### Mylan, Inc (The United States) ..... 71

##### Nippon Kayaku Co., Ltd. (Japan)..... 72

##### Pfizer, Inc. (The United States) ..... 73

##### Reliance Life Sciences Pvt. Ltd. (India)..... 74

##### Sandoz International GmbH (Germany) ..... 75

##### Shanghai Henlius Biotech, Inc. (China) ..... 76

##### STADA Arzneimittel AG (Germany) ..... 78

##### Teva Pharmaceutical Industries Limited (Israel)..... 79

##### Wockhardt Limited (India) ..... 79

#### 6. KEY BUSINESS AND PRODUCT TRENDS .....80

##### AbbVie Inc and Frontier Collaborate on Novel Therapies and E3 Degraders..... 80

##### Eli Lilly and UHG Collaborate on Bamlanivimab (LY-CoV555) Antibody Study ..... 80

##### Merck Receives FDA Review Acceptance for KEYTRUDA® (pembrolizumab) Plus Chemotherapy..... 80

##### Samsung Bioepis and Biogen File U.S FDA Acceptance of SB11 Biosimilar ..... 81

##### EMA Approves Roche's Xofluza® Biosimilar ..... 81

##### Genor's New Drug Application for GB242 Infliximab Biosimilar is Under Review by NMPA ..... 82

##### NeuClone Discloses it's Stelara® Biosimilar Candidate Clinical Trials..... 82

##### FDA Approval for Anti-IL-4Rα Monoclonal Antibody ..... 82

##### Pfizer's NYVEPRIA™ Biosimilar Receives FDA Approval ... 83

##### Biocon Ltd Establishes Biosimilar Plant in India..... 83

##### Boehringer Acquires Northern Biologics, Inc. .... 84

##### Biocon Ltd. and Mylan N.V Unveils Fulphila® Biosimilar.. 84

##### mAbxience Establishes New Biosimilar Antibody Plant in Argentina ..... 84

##### CHMP Recommends RUXIENCE™ Biosimilar ..... 85

##### FDA Approval for ABP 798, a Biosimilar Candidate to Rituxan® ..... 85

##### Amgen Receives FDA Approval for its AVSOLA™ (Infliximab-axxq) Biosimilar Antibody ..... 85

##### 3SBio, Inc and Verseau Agree on Monoclonal Antibody Development - VTX-0811..... 86

##### Boehringer Ingelheim Discloses GioTag Study Results.... 86

##### Dr. Reddy's Lab Unveils Versavo® Biosimilar ..... 86

##### Allergan and Gedeon Receive FDA Approval for VRAYLAR® Drug Use..... 87

##### Samsung Bioepis Signs Biosimilars Development and Marketing Agreement with C-Bridge Capital ..... 87

##### Biosimilar Association of Samsung Bioepis and 3SBio..... 87

##### Kashiv Pharma Renamed as KashivBioSciences Post Acquiring Adello Biologics ..... 88

##### Intas Unveils New Pegylated G-CSF Biosimilar in Europe 88

##### Japanese Release of Trastuzumab and Agalsidase Beta Biosimilar ..... 88

##### Epoetin Alfa and Pegfilgrastim Biosimilars Now Accessible In the US at Considerable Concession..... 89

##### Biosimilars of Insulin Glargine Introduced in South Korea and the UK..... 89

##### CNDA Accepted Review of Adalimumab Biosimilar ..... 89

##### Filgrastim Biosimilar Application Submitted to the US FDA... 89

##### European Commercial Release of Amgevita and Imraldi 90

##### MHLW of Japan Received Approval Application for Dual Darbepoetin Alfa Copy Biologics..... 90

##### Evaluation of Adalimumab Biosimilar SB5 by USFDA ..... 90

##### Acceptance of Approval Application by CFDA for Adalimumab Biosimilar..... 90

##### Review Acceptance for MabionCD20 by EMA and Rituxan Expanded the Therapeutic Range ..... 91

##### Dr Reddy's Introduces Hervycta, A Trastuzumab Biosimilar in India..... 91

##### Apotex Influence Canadian Biosimilar Market..... 91

##### Resubmission of Marketing Approval of Biosimilar Rituximab to FDA by Celltrion..... 92

##### Refusal of Trastuzumab and Rituximab Biosimilars Approval Applications by FDA..... 92

##### Rejection of Rituximab and Trastuzumab of Celltrion/Teva by FDA ..... 92

##### Amgen and Allergan Authorize ABP 980 Biosimilar ..... 93

##### OntruzantTrastuzumab Biosimilar Released in the UK.... 93

##### Commercialization of Trastuzumab Biosimilar in South Korea By Daewoong ..... 93

##### Commercial Release of Adalimumab Biosimilar in India by Hetero ..... 94

##### Production of Denosumab Biosimilar in Australia..... 94

#### 7. GLOBAL MARKET OVERVIEW .....95

##### 7.1 Global Biosimilars Market Overview by Product Type..... 96

##### 7.1.1 Global Biosimilars Product Types Market Overview by Geographic Region ..... 98

##### 7.1.1.1 Monoclonal Antibodies..... 98

##### 7.1.1.2 Erythropoietin..... 100

##### 7.1.1.3 G-CSF ..... 102

##### 7.1.1.4 Insulin ..... 104

##### 7.1.1.5 Other Product Types ..... 106

##### 7.2 Global Biosimilars Market Overview by Therapeutic Area ..... 108

##### 7.2.1 Global Biosimilars Therapeutic Area Market Overview by Geographic Region..... 110

##### 7.2.1.1 Oncology..... 110

##### 7.2.1.2 Autoimmune Disorders..... 112

##### 7.2.1.3 Blood Disorders ..... 114

##### 7.2.1.4 Growth Hormone Deficiency ..... 116

##### 7.2.1.5 Other Therapeutic Areas..... 118

#### PART B: REGIONAL MARKET PERSPECTIVE ... 120

#### REGIONAL MARKET OVERVIEW .....122

#### 8. EUROPE .....122

##### 8.1 European Biosimilars Market Overview by Geographic Region ..... 123

8.2 European Biosimilars Market Overview by Product Type.....	125	9.2.1.1 Monoclonal Antibodies.....	192	Intas Pharmaceuticals Ltd (India).....	270
8.2.1 European Biosimilars Product Types Market Overview by Geographic Region.....	127	9.2.1.2 Erythropoietin.....	194	Lg Chem (South Korea).....	271
8.2.1.1 Monoclonal Antibodies.....	127	9.2.1.3 G-CSF.....	196	Lupin Limited (India).....	272
8.2.1.2 Erythropoietin.....	129	9.2.1.4 Insulin.....	198	Nippon Kayaku Co., Ltd. (Japan).....	273
8.2.1.3 G-CSF.....	131	9.2.1.5 Other Product Types.....	200	Reliance Life Sciences Pvt., Ltd. (India).....	274
8.2.1.4 Insulin.....	133	9.3 North American Biosimilars Market Overview by Therapeutic Area.....	202	Samsung Biologics Co., Ltd. (South Korea).....	274
8.2.1.5 Other Product Types.....	135	9.3.1 North American Biosimilars Therapeutic Area Market Overview by Geographic Region.....	204	Shanghai Henlius Biotech, Inc. (China).....	275
8.3 European Biosimilars Market Overview by Therapeutic Area.....	137	9.3.1.1 Oncology.....	204	Wockhardt Limited (India).....	277
8.3.1 European Biosimilars Therapeutic Area Market Overview by Geographic Region.....	139	9.3.1.2 Autoimmune Disorders.....	206	Zydus Cadila (India).....	278
8.3.1.1 Oncology.....	139	9.3.1.3 Blood Disorders.....	208		
8.3.1.2 Autoimmune Disorders.....	141	9.3.1.4 Growth Hormone Deficiency.....	210	10.5 Country-wise Analysis of Asia-Pacific Biosimilars Market.....	279
8.3.1.3 Blood Disorders.....	143	9.3.1.5 Other Therapeutic Areas.....	212	<b>10.5.1 China.....</b>	<b>279</b>
8.3.1.4 Growth Hormone Deficiency.....	145	9.4 Major Market Players.....	214	10.5.1.1 Chinese Biosimilars Market Overview by Product Type.....	280
8.3.1.5 Other Therapeutic Areas.....	147	Amgen Inc. (The United States).....	214	10.5.1.2 Chinese Biosimilars Market Overview by Therapeutic Area.....	282
8.4 Major Market Players.....	149	Apotex, Inc. (Canada).....	215	<b>10.5.2 India.....</b>	<b>284</b>
AXXO GmbH (Germany).....	149	Biogen, Inc. (The United States).....	215	10.5.2.1 Indian Biosimilars Market Overview by Product Type.....	285
BIOCAD (Russia).....	150	Coherus BioSciences (The United States).....	216	10.5.2.2 Indian Biosimilars Market Overview by Therapeutic Area.....	287
Bioton S.A. (Poland).....	151	Creative Biomart, Inc. (The United States).....	217	<b>10.5.3 Japan.....</b>	<b>289</b>
C.H. Boehringer Sohn Ag & Co., Kg. (Germany).....	151	Eli Lilly and Company (The United States).....	218	10.5.3.1 Japanese Biosimilars Market Overview by Product Type.....	290
F. Hoffmann-La Roche Ltd (Switzerland).....	152	Kashiv Biosciences Llc (The United States).....	219	10.5.3.2 Japanese Biosimilars Market Overview by Therapeutic Area.....	292
Fresenius Kabi Ag (Germany).....	153	Mylan, Inc (The United States).....	220	<b>10.5.4 South Korea.....</b>	<b>294</b>
Insud Pharma SL (Spain).....	154	Pfizer, Inc. (The United States).....	221	10.5.4.1 South Korean Biosimilars Market Overview by Product Type.....	295
mAbxience SA (Spain).....	154	Probiomed S.A. De C.V (Mexico).....	222	10.5.4.2 South Korean Biosimilars Market Overview by Therapeutic Area.....	297
Sandoz International GmbH (Germany).....	155			<b>10.5.5 Rest of Asia-Pacific.....</b>	<b>299</b>
STADA Arzneimittel AG (Germany).....	156	9.5 Country-wise Analysis of North American Biosimilars Market.....	223	10.5.5.1 Rest of Asia-Pacific Biosimilars Market Overview by Product Type.....	300
8.5 Country-wise analysis of European Biosimilars Market.....	157	<b>9.5.1 The United States.....</b>	<b>223</b>	10.5.5.2 Rest of Asia-Pacific Biosimilars Market Overview by Therapeutic Area.....	302
<b>8.5.1 Germany.....</b>	<b>157</b>	9.5.1.1 United States Biosimilars Market Overview by Product Type.....	224	<b>11. REST OF WORLD.....</b>	<b>304</b>
8.5.1.1 German Biosimilars Market Overview by Product Type.....	158	9.5.1.2 United States Biosimilars Market Overview by Therapeutic Area.....	226	11.1 Rest of World Biosimilars Market Overview by Geographic Region.....	305
8.5.1.2 German Biosimilars Market Overview by Therapeutic Area.....	160	<b>9.5.2 Canada.....</b>	<b>228</b>	11.2 Rest of World Biosimilars Market Overview by Product Type.....	307
<b>8.5.2 United Kingdom.....</b>	<b>162</b>	9.5.2.1 Canadian Biosimilars Market Overview by Product Type.....	229	11.2.1 Rest of World Biosimilars Product Types Market Overview by Geographic Region.....	309
8.5.2.1 United Kingdom Biosimilars Market Overview by Product Type.....	163	9.5.2.2 Canadian Biosimilars Market Overview by Therapeutic Area.....	231	11.2.1.1 Monoclonal Antibodies.....	309
8.5.2.2 United Kingdom Biosimilars Market Overview by Therapeutic Area.....	165	<b>9.5.3 Mexico.....</b>	<b>233</b>	11.2.1.2 Erythropoietin.....	311
<b>8.5.3 France.....</b>	<b>167</b>	9.5.3.1 Mexican Biosimilars Market Overview by Product Type.....	234	11.2.1.3 G-CSF.....	313
8.5.3.1 French Biosimilars Market Overview by Product Type.....	168	9.5.3.2 Mexican Biosimilars Market Overview by Therapeutic Area.....	236	11.2.1.4 Insulin.....	315
8.5.3.2 French Biosimilars Market Overview by Therapeutic Area.....	170	<b>10. ASIA-PACIFIC.....</b>	<b>238</b>	11.2.1.5 Other Product Types.....	317
<b>8.5.4 Spain.....</b>	<b>172</b>	10.1 Asia-Pacific Biosimilars Market Overview by Geographic Region.....	239	11.3 Rest of World Biosimilars Market Overview by Therapeutic Area.....	319
8.5.4.1 Spanish Biosimilars Market Overview by Product Type.....	173	10.2 Asia-Pacific Biosimilars Market Overview by Product Type.....	241	11.3.1 Rest of World Biosimilars Therapeutic Area Market Overview by Geographic Region.....	321
8.5.4.2 Spanish Biosimilars Market Overview by Therapeutic Area.....	175	10.2.1 Asia-Pacific Biosimilars Product Types Market Overview by Geographic Region.....	243	11.3.1.1 Oncology.....	321
<b>8.5.5 Italy.....</b>	<b>177</b>	10.2.1.1 Monoclonal Antibodies.....	243	11.3.1.2 Autoimmune Disorders.....	323
8.5.5.1 Italian Biosimilars Market Overview by Product Type.....	178	10.2.1.2 Erythropoietin.....	245	11.3.1.3 Blood Disorders.....	325
8.5.5.2 Italian Biosimilars Market Overview by Therapeutic Area.....	180	10.2.1.3 G-CSF.....	247	11.3.1.4 Growth Hormone Deficiency.....	327
<b>8.5.6 Rest of Europe.....</b>	<b>182</b>	10.2.1.4 Insulin.....	249	11.3.1.5 Other Therapeutic Areas.....	329
8.5.6.1 Rest of Europe Biosimilars Market Overview by Product Type.....	183	10.2.1.5 Other Product Types.....	251	11.4 Major Market Players.....	331
8.5.6.2 Rest of Europe Biosimilars Market Overview by Therapeutic Area.....	185	10.3 Asia-Pacific Biosimilars Market Overview by Therapeutic Area.....	253	AMEGA Biotech (Argentina).....	331
<b>9. NORTH AMERICA.....</b>	<b>187</b>	10.3.1 Asia-Pacific Biosimilars Therapeutic Area Market Overview by Geographic Region.....	255	Teva Pharmaceutical Industries Limited (Israel).....	332
9.1 North American Biosimilars Market Overview by Geographic Region.....	188	10.3.1.1 Oncology.....	255	11.5 Country-wise Analysis of Rest of World Biosimilars Market.....	333
9.2 North American Biosimilars Market Overview by Product Type.....	190	10.3.1.2 Autoimmune Disorders.....	257	<b>11.5.1 Brazil.....</b>	<b>333</b>
9.2.1 North American Biosimilars Product Types Market Overview by Geographic Region.....	192	10.3.1.3 Blood Disorders.....	259	11.5.1.1 Brazilian Biosimilars Market Overview by Product Type.....	334
		10.3.1.4 Growth Hormone Deficiency.....	261	11.5.1.2 Brazilian Biosimilars Market Overview by Therapeutic Area.....	336
		10.3.1.5 Other Therapeutic Areas.....	263		
		10.4 Major Market Players.....	265		
		Celltrion, Inc. (South Korea).....	265		
		Dong-A Socio Group (South Korea).....	266		
		Dr. Reddy's Laboratories Ltd. (India).....	267		
		Genor Biopharma Co., Ltd. (China).....	268		
		Hetero Drugs Limited (India).....	269		



<b>11.5.2 Israel.....</b>	<b>338</b>	11.5.3.2 Other Countries Biosimilars Market Overview by Therapeutic Area .....	346	<b>PART D: ANNEXURE.....</b>	<b>355</b>
11.5.2.1 Israeli Biosimilars Market Overview by Product Type .....	339	<b>PART C: GUIDE TO THE INDUSTRY.....</b>	<b>348</b>	1. RESEARCH METHODOLOGY .....	355
11.5.2.2 Israeli Biosimilars Market Overview by Therapeutic Area .....	341	1. NORTH AMERICA .....	348	2. FEEDBACK .....	357
<b>11.5.3 Other Countries .....</b>	<b>343</b>	2. EUROPE.....	349		
11.5.3.1 Other Countries Biosimilars Market Overview by Product Type.....	344	3. ASIA-PACIFIC.....	351		
		4. REST OF WORLD.....	354		

## About Industry Experts

Industry Experts’ market research, backed by years of experience and an analytical team dedicated to providing the most optimal business solutions, has been specifically designed to provide a variety of benefits, both current and future. Our leading-edge publications make the life easy for corporate strategists, investors, analysts and researchers, startups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

Business intelligence provides the critical link between comprehending prevailing market conditions and devising strategies to maximize parameters, such as revenues, profits and return on investment in order to gain market share. The significance of market research can be largely understood through the range of factors that impact businesses. These can comprise market size (current and projected), geographic market reach and demand and supply scenario, to name a few. Our ongoing quest to collect up to date and accurate information by conducting online surveys, personal interviews, taking the opinions of senior level executives will enable us to serve our clients better in every possible aspect.

[More about Industry Experts](#)



**Industry Experts, Inc.**  
 14726 Ramona Ave, Suite S2  
 Chino, CA 91710  
 Greater Los Angeles  
 United States  
 Phone: +1-320-iXPERTS (497-3787)  
 Email: [info@industry-experts.com](mailto:info@industry-experts.com)

**India Office**  
 1-7-19/C, Street No. 8, Habsiguda  
 Hyderabad – 500007  
 India  
 Phone: +91-40-4018-1314  
 Fax: +91-40-2715-7746  
 Website: <http://industry-experts.com>